Quarterly report pursuant to Section 13 or 15(d)

Development Awards (Details Narrative)

v3.5.0.2
Development Awards (Details Narrative)
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2016
USD ($)
Apr. 20, 2015
USD ($)
Installments
May 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2016
USD ($)
Development Award [Line Items]          
Deferred revenue     $ 1,250,000    
Cystic Fibrosis Foundation Therapeutics Inc [Member]          
Development Award [Line Items]          
Amount received upon execution of award agreement $ 1,000,000     $ 1,250,000 $ 1,500,000
Resunab [Member]          
Development Award [Line Items]          
Number of installments | Installments   3      
Percentage of royalty over receivables under agreement   500.00%      
Payment due period after the first commercial sale   90 days      
Royalty payment, sales target   $ 500,000,000      
Resunab [Member] | Upon Transfer Sale Or Licensing [Member]          
Development Award [Line Items]          
Royalty payable   15,000,000      
Resunab [Member] | Cystic Fibrosis Foundation Therapeutics Inc [Member]          
Development Award [Line Items]          
Amount received upon execution of award agreement     $ 1,250,000 1,250,000  
Deferred revenue       $ 3,500,000  
Remaining amount receivable upon achievement of certain milestones         $ 1,500,000
Maximum [Member] | Resunab [Member]          
Development Award [Line Items]          
Development award received   5,000,000      
Maximum [Member] | Resunab [Member] | Upon Commercialization Of The Product [Member]          
Development Award [Line Items]          
Royalty payable   25,000,000      
Maximum [Member] | Resunab [Member] | Upon Reaching The Sales Target [Member]          
Development Award [Line Items]          
Royalty payable   $ 5,000,000